RICHMOND, Va. / May 13, 2024 / Business Wire / Owens & Minor, Inc. (NYSE: OMI), a global healthcare solutions company that provides healthcare products for home-based care, self-manufactured products, proprietary product portfolio, distribution services and innovative technology, announced today that Alex Bruni, the Company’s Executive Vice President and Chief Financial Officer and Jonathan Leon, the Company’s Senior Vice President-Finance and Corporate Treasurer, will be participating in a webcasted fireside chat at 5:20 p.m. Eastern Daylight Time on Wednesday, May 15, 2024 at BofA Securities’ 2024 Health Care Conference in Las Vegas, Nevada. Owens & Minor is also hosting one-on-one meetings with investors at the conference.
Please visit the investor relations page of the Owens & Minor website available at investors.owens-minor.com/events-and-presentations/ at least 10 minutes in advance to register for the live webcast of the discussion. A replay of the webcast can be accessed following the presentation at the link provided above.
About Owens & Minor
Owens & Minor, Inc. (NYSE: OMI) is a Fortune 500 global healthcare solutions company providing essential products and services that support care from the hospital to the home. For over 100 years, Owens & Minor and its affiliated brands, Apria®, Byram® and HALYARD*, have helped to make each day better for the patients, providers, and communities we serve. Powered by more than 20,000 teammates worldwide, Owens & Minor delivers comfort and confidence behind the scenes so healthcare stays at the forefront. Owens & Minor exists because every day, everywhere, Life Takes Care™. For more information about Owens & Minor and our affiliated brands, visit owens-minor.com or follow us on LinkedIn and Instagram.
Last Trade: | US$12.55 |
Daily Change: | -0.01 -0.08 |
Daily Volume: | 126,667 |
Market Cap: | US$967.730M |
December 02, 2024 November 04, 2024 September 10, 2024 September 09, 2024 August 02, 2024 |
Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...
CLICK TO LEARN MORECompass Therapeutics is a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases. The company's scientific focus is on the relationship between angiogenesis, the immune system, and tumor growth...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB